gerd semaglutide and Semaglutide and heartburn Diabetes patients on Ozempic-like drugs

The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes

Here, some categories and what the science shows: Weight and appetite-related peptides These are the only peptides consistently shown to support meaningful fat loss: Semaglutide (Wegovy, Ozempic) Tirzepatide (Zepbound, Mounjaro) These medications are known as GLP-1 receptor agonists (tirzepatide also acts on GIP)

This makes Tirzepatide a promising option for those looking to lose weight and manage their blood sugar levels

The weight loss results timeline typically spans several months, with the most noticeable changes occurring after three months

Retatrutide is not FDA-approved and won't be available until 2027-2028 at the earliest

The immuno-modulatory effects of GLP-1RAs also suggest their potential in T1DM